Search

Displaying results 2621 - 2630 of 7604 in total
  1. Drug

    Coccidioides immitis spherule

    go.drugbank.com/drugs/DB11294
    Approved

    Coccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

  2. Drug

    Tiotropium

    go.drugbank.com/drugs/DB01409
    ApprovedInvestigational

    [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation. … [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]

    Categories: Agents to Treat Airway Disease
  3. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    FDA approved on July 31, 2009.

  4. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.

    Synonyms: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
  5. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  6. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    [A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. … [A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165]

    Categories: Analgesics, Non-Narcotic
  7. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single

  8. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    or unexplained chronic cough (UCC) when no diagnosable cause for the cough can be determined. … [L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment

  9. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    [L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis … Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases of acute liver injury, the use of vardenafil has not been linked to hepatotoxic effects.

  10. Drug

    Lycopene

    go.drugbank.com/drugs/DB11231
    Approved

    Lycopene is a non-essential human nutrient that is classified as a non-provitamin A carotenoid pigment since it lacks a terminal beta-ionone ring [A27242] and does not mediate vitamin A activity. … Lycopene is a naturally occurring red carotenoid pigment that is responsible for red to pink colors seen in tomatoes, pink grapefruit, and other foods [A27242].

    Mixtures: Shine CO-Q Plus